United Therapeutics Corporation (UTHR)

Fixed asset turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 2,877,400 2,756,200 2,616,700 2,498,300 2,327,500 2,204,300 2,110,900 1,981,300 1,936,300 1,860,000 1,788,700 1,768,300 1,685,500 1,655,200 1,590,600 1,506,100 1,483,300 1,409,500 1,430,900 1,442,500
Property, plant and equipment US$ in thousands — — — — — — 938,900 896,500 861,500 840,800 791,400 784,400 780,900 726,700 715,700 713,700 731,600 736,400 744,200 739,200
Fixed asset turnover — — — — — — 2.25 2.21 2.25 2.21 2.26 2.25 2.16 2.28 2.22 2.11 2.03 1.91 1.92 1.95

December 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $2,877,400K ÷ $—K
= —

The fixed asset turnover ratio for United Therapeutics Corporation has shown a generally increasing trend over the period from March 31, 2020, to June 30, 2023. The ratio increased from 1.95 in March 2020 to a peak of 2.28 in September 2021, indicating that the company generated $2.28 in revenue for every dollar invested in fixed assets during that period.

This suggests that United Therapeutics has been efficient in utilizing its fixed assets to generate sales revenue. A higher fixed asset turnover ratio is generally favorable as it indicates the company is efficiently using its fixed assets to generate sales.

However, there was a slight decline in the ratio towards the end of the period, reaching 2.25 in June 2023. This slight decline could be due to various factors such as changes in the company's asset base, sales volume, or capital expenditure.

It is notable that the data is not available for the period from September 30, 2023, onwards, so it is unclear how the ratio evolved beyond June 2023. Monitoring the fixed asset turnover ratio over time can provide insights into the efficiency of United Therapeutics' fixed asset utilization and operational performance.